Dara Keian Dayani of Los Angeles, California, is a commercial strategy advisor for oncology, nephrology, and rare diseases. He currently serves as senior director of US marketing at Vera Therapeutics, leading brand strategy, commercialization planning, and market shaping for kidney disease drugs while driving cross-functional alignment and team leadership. A cooking and working out enthusiast, Dara Keian Dayani holds a Doctor of Philosophy (PhD) degree in pharmaceutical science from Northeastern University in Boston, Massachusetts, where he achieved a Dean's Scholarship and an Honors Distinction.
Dara Keian Dayani’s professional path began at Seagen in 2019 as senior manager for Adcetris global insights, where he supported brand planning, US marketing initiatives, Canadian launches, national field engagement, and major promotional programs. He later advanced to director of strategy for breast and colorectal oncology, leading pivotal launch preparations, developing diagnostics strategy, overseeing performance metrics, organizing launch readiness reviews, and guiding national brand planning while collaborating closely with clinical and opinion-leader communities.
Dara Keian Dayani later joined Pfizer Oncology in 2024 as US breast cancer portfolio strategy lead, where he directed integrated franchise strategy, above-brand campaigns, cross-brand marketing tools, advisory boards, and executive communications for the franchise vice president. During his career, he has earned significant internal recognition, including multiple “IMPACT” awards.